CoChat

Next-generation AAV vectors—do not judge a virus (only) by its cover

Domenger, Claire, Grimm, Dirk · 2019 · Human Molecular Genetics

The DOI matches its Crossref record; 149 of the 150 references it cites were found in a registry or an index.

Abstract

Recombinant adeno-associated viruses (AAV) are under intensive investigation in numerous clinical trials after they have emerged as a highly promising vector for human gene therapy. Best exemplifying their power and potential is the authorization of three gene therapy products based on wild-type AAV serotypes, comprising Glybera (AAV1), Luxturna (AAV2) and, most recently, Zolgensma (AAV9). Nonetheless, it has also become evident that the current AAV vector generation will require improvements in transduction potency, antibody evasion and cell/tissue specificity to allow the use of lower and safer vector doses. To this end, others and we devoted substantial previous research to the implementation and application of key technologies for engineering of next-generation viral capsids in a high-throughput ‘top-down’ or (semi-)rational ‘bottom-up’ approach. Here, we describe a set of recent complementary strategies to enhance features of AAV vectors that act on the level of the recombinant cargo. As examples that illustrate the innovative and synergistic concepts that have been reported lately, we highlight (i) novel synthetic enhancers/promoters that provide an unprecedented degree of AAV tissue specificity, (ii) pioneering genetic circuit designs that harness biological (microRNAs) or physical (light) triggers as regulators of AAV gene expression and (iii) new insights into the role of AAV DNA structures on vector genome stability, integrity and functionality. Combined with ongoing capsid engineering and selection efforts, these and other state-of-the-art innovations and investigations promise to accelerate the arrival of the next generation of AAV vectors and to solidify the unique role of this exciting virus in human gene therapy.

Overview

Integrity signals

Registry

Crossref · 10.1093/hmg/ddz148

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 149 references

Cited by

See all 149

Metadata

Authors
Domenger, C., & Grimm, D.
Affiliations
University Hospital Heidelberg (DE)
Corresponding author
Grimm, Dirk
Venue
Human Molecular Genetics
Published
2019-07-02
Volume
28
Issue
R1
Pages
R3-R14
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
OpenAlex
W2954423091
Cited by
147
References
150
Citations by year
2026: 19 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 24 · 2021: 21 · 2020: 24 · 2019: 2
FWCI
2.35
Type
journal article
Language
en
Open access
closed
Locations
  • Human Molecular Genetics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • German Research Foundation
  • German Center for Infection Research (TTU-HIV 04.815, TTU-HIV 04.803)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Keywords
adeno-associated virus vectors, gene therapy vectors, capsid engineering, tissue-specific promoters, synthetic enhancers, synthetic gene circuits, microRNA regulation, antibody escape
MeSH terms
Dependovirus, Animals, Enhancer Elements, Genetic, Gene Expression Regulation, Genetic Engineering, Genetic Vectors, Humans, Promoter Regions, Genetic, Transduction, Genetic, Genetic Therapy, Transgenes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Next-generation AAV vectors—do not judge a virus (only) by its cover. https://app.cochat.ai/papers/10.1093/hmg/ddz148
The paper
Domenger, C., & Grimm, D. (2019). Next-generation AAV vectors—do not judge a virus (only) by its cover. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddz148

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.